title: Vitreo-retinal hemorrhage after thrombolysis in a patient with acute ischemic stroke: a case report.
abstract: OBJECTIVE
  Bleeding is the major side effect of thrombolysis with alteplase (tissue plasminogen activator, t-PA) used for the treatment of acute ischemic stroke. Life-threatening intracranial, retroperitoneal, gastrointestinal, respiratory, and genitourinary bleeding can occur with the use of t-PA. Vitreo-retinal bleeding in the context of acute ischemic stroke treatment has not been reported in the literature before and therefore is not posed as a potential risk during decision making. Here we describe the first reported case of vitreo-retinal hemorrhage due to alteplase administration in a patient with acute ischemic stroke.
  
  
  CONCLUSIONS
  An 84-year-old white male presented to the emergency room with complaints of right arm and leg weakness. The onset of symptoms was approximately 30 min prior to presentation to the emergency room. After ruling out contraindications including the presence of hemorrhage on head CT scan, patient was administered alteplase within 2 hours of symptom onset. Four hours after the administration of alteplase, the patient developed right-sided vision changes. A repeat CT scan demonstrated a newly developed right intraocular hemorrhage. Throughout the hospital course, patient's neurological status improved, but he continued to have right-sided visual loss.
  
  
  CONCLUSIONS
  Clinicians should be aware of the potential for ocular hemorrhage especially in high-risk patients. The likelihood of a subsequent vision-loss needs to be therefore discussed with the patient and family in such situations.
authors.affiliation: Pharmacy, Advocate Christ Medical Center Oak Lawn, IL, USA.
authors.forename: Mary
authors.initials: M
authors.lastname: Hormese
authors.forename: Melvin
authors.initials: M
authors.lastname: Wichter